Reporte de caso

← vista completa

Publicado el 26 de noviembre de 2015 | http://doi.org/10.5867/medwave.2015.10.6323

Inmunoglobulina intravenosa en el tratamiento del síndrome de Morvan secundario a la recurrencia de un carcinoma tímico

Intravenous immunoglobulin therapy in Morvan syndrome secondary to recurrent thymic carcinoma

Gabriel Horta Baas

Abstract

Morvan's syndrome is a rare autoimmune channelopathy. A case of Morvan's syndrome is presented as a paraneoplastic syndrome associated to the recurrence of a well-differentiated thymic carcinoma, which showed a good clinical response to treatment with intravenous immunoglobulin.

This article does not have an English version.

Esta obra de Medwave está bajo una licencia Creative Commons Atribución-NoComercial 3.0 Unported. Esta licencia permite el uso, distribución y reproducción del artículo en cualquier medio, siempre y cuando se otorgue el crédito correspondiente al autor del artículo y al medio en que se publica, en este caso, Medwave.

Autores

Gabriel Horta Baas

Servicio de Medicina Interna, Unidad Médica de Alta Especialidad, Centro Médico Nacional de Occidente, Instituto Mexicano del Seguro Social, Guadalajara, Jalisco, México

gabho@hotmail.com

Belisario Domínguez 1000, Colonia Independencia Oriente, Guadalajara, Jalisco, México

Figures

Article has no figures.

Foro

No hay mensajes

Historial

Citación Horta Baas G. Intravenous immunoglobulin therapy in Morvan syndrome secondary to recurrent thymic carcinoma. Medwave 2015;15(10):e6323 doi: 10.5867/medwave.2015.10.6323

Envío 04/05/2015

Aceptación 07/11/2015

Publicación 26/11/2015

Indice

Métricas del artículo

Vistas en HTML

448

Descargas en PDF

51

Total

499

Notas

Keywords

Morvan's syndrome, intravenous immunoglobulins, thymic carcinoma, thymoma

Provenance and peer review

reviewed by four external peer reviewers, double-blind

Referencias

  1. Ruggieri VL, Arberas CL. [Neuromuscular hereditary channelopathies: non-dystrophic myotonias, paramyotonias and periodic paralysis]. Rev Neurol. 2002 Jan 16-31;34(2):150-6. | PubMed
  2. Irani SR, Pettingill P, Kleopa KA, Schiza N, Waters P, Mazia C, et al. Morvan syndrome: clinical and serological observations in 29 cases. Ann Neurol. 2012 Aug;72(2):241-55. | CrossRef | PubMed
  3. Lee W, Day TJ, Williams DR. Clinical, laboratory and electrophysiological features of Morvan's fibrillary chorea. J Clin Neurosci. 2013 Sep;20(9):1246-9. | CrossRef | PubMed
  4. Gutmann L, Gutmann L. Myokymia and neuromyotonia 2004. J Neurol. 2004 Feb;251(2):138-42. | PubMed
  5. Rose MR. Neurological channelopathies. BMJ. 1998 Apr 11;316(7138):1104-5. | PubMed
  6. Panagariya A, Kumar H, Mathew V, Sharma B. Neuromyotonia: clinical profile of twenty cases from northwest India. Neurol India. 2006 Dec;54(4):382-6. | PubMed
  7. Liguori R, Vincent A, Clover L, Avoni P, Plazzi G, Cortelli P, et al. Morvan's syndrome: peripheral and central nervous system and cardiac involvement with antibodies to voltage-gated potassium channels. Brain. 2001 Dec;124(Pt 12):2417-26. | PubMed
  8. Gállego Pérez-Larraya J, Dalmau J. [Classic paraneoplastic syndromes: diagnostic and treatment approach]. Neurologia. 2008 Sep;23(7):441-8. | PubMed
  9. Montojo MT, Petit-Pedrol M, Graus F, Dalmau J. Clinical spectrum and diagnostic value of antibodies against the potassium channel related protein complex. Neurologia. 2015 Jun;30(5):295-301. | CrossRef | PubMed
  10. Merchut MP. Management of voltage-gated potassium channel antibody disorders. Neurol Clin. 2010 Nov;28(4):941-59. | CrossRef | PubMed
  11. Abou-Zeid E, Boursoulian LJ, Metzer WS, Gundogdu B. Morvan syndrome: a case report and review of the literature. J Clin Neuromuscul Dis. 2012 Jun;13(4):214-27. | CrossRef | PubMed
  12. Cottrell DA, Blackmore KJ, Fawcett PR, Birchall D, Vincent A, Barnard S,et al. Sub-acute presentation of Morvan's syndrome after thymectomy. J Neurol Neurosurg Psychiatry. 2004 Oct;75(10):1504-5. | PubMed
  13. Bataller L, Dalmau J. Paraneoplastic neurologic syndromes. Neurol Clin N Am. 21:221-227. | CrossRef
  14. van den Berg JS, van Engelen BG, Boerman RH, de Baets MH. Acquired neuromyotonia: superiority of plasma exchange over high-dose intravenous human immunoglobulin. J Neurol. 1999 Jul;246(7):623-5. | PubMed
  15. Graves D, Vernino S. Immunotherapies in neurologic disorders. Med Clin North Am. 2012 May;96(3):497-523, x. | CrossRef | PubMed
  16. Skeie GO, Apostolski S, Evoli A, Gilhus NE, Hart IK, Harms L, et al. Guidelines for the treatment of autoimmune neuromuscular transmission disorders. Eur J Neurol. 2006 Jul;13(7):691-9. | PubMed
  17. Kivity S, Katz U, Daniel N, Nussinovitch U, Papageorgiou N, Shoenfeld Y. Evidence for the use of intravenous immunoglobulins--a review of the literature. Clin Rev Allergy Immunol. 2010 Apr;38(2-3):201-69. | CrossRef | PubMed
  18. Bayry J, Negi VS, Kaveri SV. Intravenous immunoglobulin therapy in rheumatic diseases. Nat Rev Rheumatol. 2011 Jun;7(6):349-59. | CrossRef | PubMed
  19. Ho WK, Wilson JD. Hypothermia, hyperhidrosis, myokymia and increased urinary excretion of catecholamines associated with a thymoma. Med J Aust. 1993 Jun 7;158(11):787-8. | PubMed
  20. Alessi G, De Reuck J, De Bleecker J, Vancayzeele S. Successful immunoglobulin treatment in a patient with neuromyotonia. Clin Neurol Neurosurg. 2000 Sep;102(3):173-5. | PubMed